Juno Therapeutics Inc (JUNO) stock falls, “Hold” rating reaffirmed by JPMorgan Chase & Co. Analysts

Juno Therapeutics Inc (NASDAQ: JUNO) shares fell on Thursday Dec 1 with lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, U.S. stocks opened with slight gains on Thursday.

The Dow Jones Industrial Average DJIA, +0.31% rose 38.22 points, or 0.2%, to 19,174, while the S&P 500 SPX, +0.01% added 2.1 points to 2,202, a rise of 0.1%.

The Nasdaq Composite Index COMP, -0.32% rose less than 1 point to 5,323, essentially unchanged on the day.
Juno Therapeutics Inc (NASDAQ: JUNO) had its Hold rating reiterated by equities researchers at JPMorgan Chase & Co. in a research note to investors. JPMorgan Chase & Co. currently has a rating of Hold on the shares. As a means of comparison, a number of other analysts have spoken on the company in recent days, and Juno Therapeutics Inc has earned a consensus one-year price target of $32.92, above the opening price of $20.51. Juno Therapeutics Inc stock has a 52-week high of $57.82. Share prices sometimes get a bounce to the upside when analysts reiterate coverage.

Juno Therapeutics Inc (NASDAQ: JUNO) shares last traded at $19.84, which is a dip of $0.21 per share or -1.05% compared to the previous closing price. Opening at $20.51, they varied from $19.65 and $20.68 throughout the day.

Juno Therapeutics Inc (NASDAQ: JUNO) now has a market cap of 2.04B.

Juno Therapeutics Inc (NASDAQ: JUNO) Average Daily Trading Volume

399,594 shares crossed the trading desk yesterday, below normal, out of a total float 59,975,000. Trading volume is likely to increase in the next few days as swing traders often use upticks in trading volume to pinpoint substantial volume growth or distribution by institutional investors.

However, just a day of high volume buy side trading is not enough to assert a trend. So market traders will continue to watch for institutional sponsorship as an indicator that financial institutions are moving forward.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors have teams of analysts researching thousands of stocks. So watching their interests is a good way to ensure you are buying the right stocks.

Juno Therapeutics Inc (NASDAQ: JUNO) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

Traders can make more impactful choices on trades when they follow the activity of professional investors.

With that in mind, Juno Therapeutics Inc (NASDAQ: JUNO) now has a 50-day MA of $27.32 and 200-day MA of $32.73. It has traded in a 52-week range between $19.41 – 57.82 and today’s last price is 65.69%% lower than the 52 week high of $57.82.

Earnings growth is an important factor to look at when buying stocks and investors seek companies that have grown their earnings by at least 25% over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *